Boston Scientific said the SIMPLAAFY trial of its WATCHMAN FLX Pro left atrial appendage closure device met its six-month primary endpoints, with aspirin alone and reduced-dose NOAC alone each noninferior to dual anti-platelet therapy. Ischemic stroke rates were equivalent at 0.7%, and bleeding was lower on the single-drug regimens. Device-related thrombus at 45 days was 0.9% on reduced-dose NOAC versus 3.4% on DAPT (P=0.01).
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
